0001814903-20-000001.txt : 20200622 0001814903-20-000001.hdr.sgml : 20200622 20200622133717 ACCESSION NUMBER: 0001814903-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200622 DATE AS OF CHANGE: 20200622 EFFECTIVENESS DATE: 20200622 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Entheon Biomedical Corp. CENTRAL INDEX KEY: 0001814903 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-369415 FILM NUMBER: 20978083 BUSINESS ADDRESS: STREET 1: 700-838 W HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 0A6 BUSINESS PHONE: (604) 562-3932 MAIL ADDRESS: STREET 1: 700-838 W HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 0A6 D 1 primary_doc.xml X0708 D LIVE 0001814903 Entheon Biomedical Corp. 3694 Marine Avenue Belcarra A1 BRITISH COLUMBIA, CANADA V3H 4R8 (604) 562-3932 BRITISH COLUMBIA, CANADA None None Corporation true 2019 Timothy Ko 3694 Marine Avenue Belcarra A1 BRITISH COLUMBIA, CANADA V3H 4R8 Executive Officer Director Brandon Schwabe 3694 Marine Avenue Belcarra A1 BRITISH COLUMBIA, CANADA V3H 4R8 Executive Officer Director Christopher Gondi 3694 Marine Avenue Belcarra A1 BRITISH COLUMBIA, CANADA V3H 4R8 Director Andrew Hegle 3694 Marine Avenue Belcarra A1 BRITISH COLUMBIA, CANADA V3H 4R8 Director Kelly Pladson 3694 Marine Avenue Belcarra A1 BRITISH COLUMBIA, CANADA V3H 4R8 Executive Officer Other Health Care No Revenues 06b false 2020-06-03 true true true true true Each Unit consists of one common share and one half of one transferable warrant. Each warrant is exercisable for one common share at Cdn $0.60 for a period of 24 months, subject to acceleration. false 0 1297096 77279 1219817 The additional $1,219,817 may be received upon the exercise of transferable warrants sold inside or outside the U.S. The U.S. dollar amount is based on the Bank of Canada daily average rate of exchange reported on 6/3/2020, which was Cdn$1.3504=USD$1.00. false 4 0 0 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false Entheon Biomedical Corp. Kelly Pladson Kelly Pladson Corporate Secretary 2020-06-15